Skip to main content

Serum and Tissue Biomarkers in the Prognosis and Treatment of Breast Cancer

  • Protocol
Book cover Tumor Marker Protocols

Part of the book series: Methods in Molecular Medicine™ ((MIMM,volume 14))

  • 444 Accesses

Abstract

Several nuclear and membrane proteins are emerging as important markers of breast-cancer behavior. There is increasing evidence that these markers have potential therapeutic as well as prognostic value in the care of breast-cancer patients.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Protocol
USD 49.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Borg A, Lennertsrand J., Stenmark-Askmalm M., Ferno M., Brisfors A, Ohrvik A., Stal O., Killander D, Lane D, and Brundell J (1995) Prognostic significance of p53 overexpression in primary breast cancer. a novel luminometric immunoassay applicable on steroid receptor cytosols. Br J Cancer 71, 1013–1017

    Article  PubMed  CAS  Google Scholar 

  2. Crowther J. R. (1995) Stages in ELISA Meth Mol Biol 42, 1–218

    CAS  Google Scholar 

  3. Dittadi R, Catozzi L., Goon M, Brazzale A, Capitanio G., Gelli M. C., Menegon A., Gardini G., Malagutti R, and Piffanelli A (1993) Comparison between western blotting, immunohistochemical, and ELlSA assay for pl85neu quantitation in breast cancer specimens Anticancer Res. 13, 1821–1824.

    PubMed  CAS  Google Scholar 

  4. El-Gendy S., Tahin Q, El-Merzabani M., El-Aaser A. A, Barnabas N J, and Russo J. (1995) Co-expression of c-erbB2 and int-2 oncogenes in invasive breast cancer. Int J. Oncol. 6, 977–984

    CAS  Google Scholar 

  5. Engrall E and Perlman P (1971) Enzyme-linked immunosorbent assay (ELISA) quantitative assay of immunoglobulin G Immunochemistry 8, 87l–879.

    Google Scholar 

  6. Gannon J. V, Greaves R, Iggo R., and Lane D. P. (1990) Activating mutations in p53 produce a common conformational effect A monoclonal antibody specific for the mutant form EMBOJ 9, 1595–1602

    CAS  Google Scholar 

  7. Kurstak E. (1986) Enzyme Immunodiagnosis Academic, Orlando, FL

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 1998 Humana Press Inc, Totowa, NJ

About this protocol

Cite this protocol

Hieken, T.J., Mehta, R.R. (1998). Serum and Tissue Biomarkers in the Prognosis and Treatment of Breast Cancer. In: Hanausek, M., Walaszek, Z. (eds) Tumor Marker Protocols. Methods in Molecular Medicine™, vol 14. Springer, Totowa, NJ. https://doi.org/10.1385/0-89603-380-5:95

Download citation

  • DOI: https://doi.org/10.1385/0-89603-380-5:95

  • Publisher Name: Springer, Totowa, NJ

  • Print ISBN: 978-0-89603-380-1

  • Online ISBN: 978-1-59259-598-3

  • eBook Packages: Springer Protocols

Publish with us

Policies and ethics